NASDAQ:CDNA CareDx (CDNA) Stock Price, News & Analysis $15.53 +0.64 (+4.30%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$14.26▼$15.6250-Day Range$7.76▼$16.1552-Week Range$4.80▼$17.03Volume416,400 shsAverage Volume885,777 shsMarket Capitalization$808.80 millionP/E RatioN/ADividend YieldN/APrice Target$16.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get CareDx alerts: Email Address CareDx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside6.2% Upside$16.50 Price TargetShort InterestBearish11.68% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.49) to ($1.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.28 out of 5 starsMedical Sector472nd out of 879 stocksMedical Laboratories Industry12th out of 17 stocks 2.3 Analyst's Opinion Consensus RatingCareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCareDx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CareDx's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.68% of the float of CareDx has been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in CareDx has recently decreased by 0.19%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCareDx does not currently pay a dividend.Dividend GrowthCareDx does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.Environmental SustainabilityThe Environmental Impact score for CareDx is -0.66. Previous Next 1.2 News and Social Media Coverage News SentimentCareDx has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CareDx this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CareDx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of CareDx is held by insiders.Read more about CareDx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CareDx are expected to grow in the coming year, from ($1.49) to ($1.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CareDx is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CareDx is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCareDx has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CareDx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).Get the full story here while you can. About CareDx Stock (NASDAQ:CDNA)CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Read More CDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDNA Stock News HeadlinesJuly 5 at 1:28 AM | americanbankingnews.comCareDx (NASDAQ:CDNA) Downgraded by StockNews.comJune 30, 2024 | americanbankingnews.comCareDx (NASDAQ:CDNA) Stock Price Up 4.6%July 8, 2024 | Stansberry Research (Ad)BUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).June 28, 2024 | americanbankingnews.comCareDx (NASDAQ:CDNA) Upgraded by StockNews.com to "Buy"June 3, 2024 | businesswire.comLandmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable PatientsMay 30, 2024 | businesswire.comAI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant CongressMay 29, 2024 | finance.yahoo.comCareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is IrrelevantMay 29, 2024 | businesswire.comCareDx to Participate in Upcoming Investor ConferencesJuly 8, 2024 | Stansberry Research (Ad)BUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).May 25, 2024 | finance.yahoo.comCareDx, Inc (CDNA)May 16, 2024 | finance.yahoo.comLandmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer BiopsiesMay 16, 2024 | businesswire.comLandmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer BiopsiesMay 15, 2024 | markets.businessinsider.comMaintaining Hold on CareDx Amid Growth, Valuation, and Uncertainty ConcernsMay 15, 2024 | markets.businessinsider.comBalanced Outlook for CareDx: Strong Performance Amid Rising CompetitionMay 15, 2024 | insidermonkey.comHere’s Why Baron Discovery Fund Reinitiated the Position in CareDx (CDNA)May 15, 2024 | markets.businessinsider.comBuy Rating Justified: CareDx’s Strong Financial Performance and Market PotentialMay 14, 2024 | msn.comRaymond James Downgrades CareDx (CDNA)May 13, 2024 | msn.comCareDx cut to market perform by Raymond James over valuationSee More Headlines Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/07/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CDNA CUSIPN/A CIK1217234 Webwww.caredxinc.com Phone(415) 287-2300Fax415-287-2450Employees635Year FoundedN/APrice Target and Rating Average Stock Price Target$16.50 High Stock Price Target$22.00 Low Stock Price Target$12.00 Potential Upside/Downside+6.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,280,000.00 Net Margins-66.59% Pretax Margin-66.61% Return on Equity-55.08% Return on Assets-37.48% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.03 Sales & Book Value Annual Sales$280.32 million Price / Sales2.89 Cash FlowN/A Price / Cash FlowN/A Book Value$4.83 per share Price / Book3.22Miscellaneous Outstanding Shares52,080,000Free Float49,896,000Market Cap$808.80 million OptionableOptionable Beta1.78 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Abhishek Jain (Age 47)CFO & Principal Accounting Officer Comp: $425.58kDr. Peter Maag Ph.D. (Age 57)Executive Director Comp: $43.23kMr. Alexander L. Johnson (Age 50)President of Patient & Testing Services Comp: $547.43kMr. John Walter Hanna Jr. (Age 44)President, CEO & Director Ms. Marica Grskovic Ph.D.Chief Operating OfficerDr. Robert N. Woodward Ph.D.Chief Scientific OfficerMr. GS JhaSenior VP, Chief Information Officer & Chief Information Security OfficerJeffrey A. NovackGeneral CounselMs. Stacey FollonSenior VP & Head of Human ResourcesMr. Kashif RathoreChief of Patient & Digital SolutionsMore ExecutivesKey CompetitorsGenetronNASDAQ:GTHFortreaNASDAQ:FTREVeracyteNASDAQ:VCYTViridian TherapeuticsNASDAQ:VRDNCelcuityNASDAQ:CELCView All CompetitorsInsiders & InstitutionsGAMMA Investing LLCBought 2,013 shares on 7/2/2024Ownership: 0.004%Jacobs Levy Equity Management Inc.Bought 92,363 shares on 5/16/2024Ownership: 2.210%Caxton Associates LPBought 47,469 shares on 5/16/2024Ownership: 0.185%California State Teachers Retirement SystemSold 3,333 shares on 5/16/2024Ownership: 0.010%Public Employees Retirement Association of ColoradoSold 847 shares on 5/15/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions CDNA Stock Analysis - Frequently Asked Questions How have CDNA shares performed this year? CareDx's stock was trading at $12.00 at the beginning of the year. Since then, CDNA stock has increased by 29.4% and is now trading at $15.53. View the best growth stocks for 2024 here. How were CareDx's earnings last quarter? CareDx, Inc (NASDAQ:CDNA) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.18. The firm had revenue of $72.05 million for the quarter, compared to analysts' expectations of $63.63 million. CareDx had a negative trailing twelve-month return on equity of 55.08% and a negative net margin of 66.59%. Who are CareDx's major shareholders? CareDx's top institutional shareholders include GAMMA Investing LLC. Insiders that own company stock include Reginald Seeto, Peter Maag, Michael Goldberg, Grace Colon, Ankur Dhingra and George Bickerstaff. View institutional ownership trends. How do I buy shares of CareDx? Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CareDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA) and Enphase Energy (ENPH). This page (NASDAQ:CDNA) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CareDx, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CareDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
